Livial (tibolone) / Organon - LARVOL DELTA

Cortical and trabecular bone changes associated with tibolone in postmenopausal women: A randomized, open-label study compared with estrogen therapy and placebo. (PubMed, J Clin Densitom) - "In this exploratory randomized study, no statistically significant between-group differences in cortical or trabecular bone parameters were detected over 12 months, and the observed changes in areal BMD did not exceed the least significant change of conventional DXA measurements. Therefore, the present study cannot establish clinically meaningful skeletal changes with tibolone. The numerical patterns observed with 3D-DXA should be considered hypothesis-generating and require confirmation in larger, adequately powered, and longer-term studies."

Journal • Osteoporosis • Rheumatology

Tibolone Use Associated With Elevated Hepatocellular Carcinoma Risk: Findings From a Nationwide Cohort. (PubMed, Int J Cancer) - "A dose-response trend was observed (P for trend = 0.043). These findings suggest a possible link between sustained tibolone use and HCC risk, warranting confirmation in larger populations and longer follow-up, ideally through well-designed prospective studies."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Association Between Menopausal Hormone Therapy and the Risk of Urologic Cancer: A National Population-Based Retrospective Cohort Study in Korea. (PubMed, J Korean Med Sci) - "MHT in postmenopausal women is significantly associated with the incidence of kidney and bladder cancers."

Journal • Retrospective data • Bladder Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urethral Cancer

Postmenopausal endometriosis: current evidence and clinical challenges in diagnosis and treatment. (PubMed, Curr Opin Obstet Gynecol) - "Evidence on postmenopausal endometriosis remains limited. Further research is needed to guide treatment, refine hormone therapy strategies, and improve long-term outcomes and quality of life."

Journal • Review • Endometriosis • Gynecology • Oncology • Ovarian Cancer • Women's Health

Efficacy of hormone therapy and phytoestrogens on the psychological symptoms of menopausal women: a systematic review, meta-analysis, and trial sequential analysis. (PubMed, Front Med (Lausanne)) - "In addition, Tibolone showed a significant improvement in depression (SMD 0.93, 95% CI 0.62-1.24)...The therapeutic strategy should be adopted based on individual patient's specific characteristics. https://www.crd.york.ac.uk/PROSPERO/, Identifier: CRD42024533658."

Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

Association between type and duration of menopausal hormone therapy and endometrial cancer risk: A population-based study. (PubMed, Int J Gynaecol Obstet) - "Endometrial cancer risk in postmenopausal women is influenced by hormone therapy type and duration. Combined estrogen-progestogen regimens are associated with lower risk, whereas prolonged tibolone use is associated with higher risk, supporting individualized and duration-based monitoring."

Journal • Endometrial Cancer • Oncology • Solid Tumor

Reverse addition protocol after endometriosis surgery (ChiCTR) - P4 | N=158 | Not yet recruiting | Sponsor: West China Second University Hospital, Sichuan University; West China Second University Hospital, Sichuan University

New P4 trial • Endometriosis • Gynecology • Women's Health

Efficacy and safety of menopausal hormone therapy for depressive symptoms in perimenopausal women: A systematic review and meta-analysis. (PubMed, J Affect Disord) - "HRT may be associated with a modest reduction in depressive symptoms in perimenopausal women; however, the magnitude of effect is small and the certainty of evidence is limited. Evidence comparing different HRT strategies remains insufficient to draw firm conclusions. Further well-designed, adequately powered randomized controlled trials are needed to clarify comparative efficacy and long-term safety."

Journal • Retrospective data • Review • CNS Disorders

Comprehensive Long-Term Risks and Benefits of Menopausal Hormone Therapy: A Systematic Review With Pooled Cardiovascular Estimates (AACE 2026) - "Local estrogen, selective estrogen receptor modulators, tibolone, and cancer survivor cohorts were excluded...Earlier initiation, closer to menopause, is associated with more favorable cardiovascular patterns. These findings supported individualized, time-sensitive MHT decisions using the lowest"

Review • Breast Cancer • Cardiovascular • Colorectal Cancer • Coronary Artery Disease • Heart Failure • Hormone Receptor Breast Cancer • Musculoskeletal Diseases • Solid Tumor • Venous Thromboembolism

Cardiovascular outcomes of menopause hormone therapy initiated in women aged ≥60 years or ≥10 years post-menopause: A systematic review of the literature (ISGE 2026) - "Intervention: All included trials evaluated oral regimens: conjugated equine estrogens, CEE plus medroxyprogesterone acetate, tibolone, and other estrogen–progestin combinations...Evidence from available RCTs—predominantly oral therapies from WHI—does not demonstrate a statistically significant increase in cardiovascular risk when MHT is initiated at ≥60 years or ≥10 years post-menopause. However, the lack of robust data on transdermal and modern regimens underscores the need for contemporary, well-designed trials to better guide clinical decision-making. This abstract is based on a peer-reviewed article published in Post Reproductive Health (2025)."

Clinical • Review • Cardiovascular • Coronary Artery Disease • Heart Failure • Venous Thromboembolism

Endometriosis in Perimenopause and postmenopause (ISGE 2026) - "Also, tibolone can be used...Gynecol Endocrinol. 2024; 40(1):2441299."

Breast Cancer • Endometriosis • Gynecology • Musculoskeletal Pain • Solid Tumor • Thyroid Gland Carcinoma • Women's Health

Menopausal hormone therapy and breast cancer: risk and management. (PubMed, Curr Opin Obstet Gynecol) - "Most healthy women can use hormone therapy safely with individualized counseling, attention to timing, and progestogen selection. Among survivors, low-dose vaginal estrogen remains appropriate for refractory GSM with oncology involvement."

Journal • Breast Cancer • Gynecology • Oncology • Solid Tumor • Women's Health

Treatment patterns of hormone therapy for menopause-associated vasomotor symptoms: analysis of the HIRA database in South Korea. (PubMed, Climacteric) - "Tibolone and combined estrogen with progestogen were the most common HTs. While the number of patients who received HT constituted approximately 1% of the estimated 9.31 million menopausal population in South Korea, most patients prescribed HT had a medical condition of interest at baseline that was a contraindication or precaution for HT. There is a need to identify additional well-tolerated, effective alternatives."

Journal

Association Between Menopausal Hormone Therapy and Cancer: A Nationwide Retrospective Cohort Study in South Korea. (PubMed, Cancer Epidemiol Biomarkers Prev) - "These findings suggest considering lower-potency progestogens in current estrogen/progestogen. This change might increase endometrial cancer risk but reduce breast cancer risk, potentially lowering overall cancer risk."

Journal • Retrospective data • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Oncology • Solid Tumor • Uterine Cancer

Reappraising Cardiovascular Risks of Tibolone in Postmenopausal Women: A Response to the Editorial by Lee and Kim. (PubMed, J Menopausal Med) - No abstract available

Journal • Cardiovascular

Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. (PubMed, Lancet Healthy Longev) - "This review found no evidence that MHT use either increases or decreases the risk of dementia in post-menopausal women. This reinforces current clinical guidance, that MHT prescription should be based on other perceived benefits and risks and not for dementia prevention. High-quality, long-term studies are needed to clarify the role of MHT and dementia risk, particularly regarding formulation, dose, route, timing, and duration of treatment, with a focus on women with premature ovarian insufficiency, early menopause, or mild cognitive impairment."

Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Women's Health

Comparative Effectiveness of Tibolone and Combined Hormone Therapy in Relieving Menopausal Insomnia. (PubMed, Womens Health Rep (New Rochelle)) - "The study suggests that tibolone and combined HT improved sleep to a similar extent after adjustment. Further comprehensive research is necessary to corroborate these observations."

HEOR • Journal • CNS Disorders • Insomnia • Sleep Disorder

Proposal of Chemical Inhibitors That Compete with the Binding of RNA Polymerase II Subunits to Essential GTPases GPN Npa3 and Gpn1. (PubMed, ACS Omega) - "Our analysis identified potential inhibitors, including atovaquone for both Npa3 and Gpn1 (docking scores: -14.4 and -13.5 kcal/mol, respectively) and tibolone for Npa3 (-13.6 kcal/mol), following flexible docking optimization. Additionally, our docking models suggest key residues in Npa3 such as F143 and W179, which may be critical for recognizing RNA polymerase II subunits and drug-like molecules. These findings can be further explored through biochemical and mutagenesis studies to assess their roles in RNA polymerase II recognition."

Journal

The Impact of Menopausal Hormone Therapy on Productivity and Health Care Utilization in Women: A Finnish Claims Database Study (ISPOR-EU 2025) - "During the first year, estrogen-progestogen was initiated by 60,7%, estrogen by 37,5% and tibolone by 1.8%... The study cohort includes nearly all women aged 40-70 years in Finland, enabling nationwide analysis of the effect of MHT on healthcare use and productivity. Clinicians and payors should consider the impact of menopausal symptoms on a woman's personal and professional life when evaluating the use of MHT."

Claims database • Clinical • HEOR

A high-performance adaptive fusion network for face anti-spoofing detection. (PubMed, Sci Rep) - "Finally, through adversarial training of domain discriminators, dual alignment of multi-source domain features and categories is achieved, effectively alleviating the problem of cross-domain data distribution differences. A large number of training and test results conducted on the four benchmark datasets of OULU-NPU, MSU-MFSD, CASIA-FASD and ReReplay Attack show that the performance of the proposed method is significantly better than that of the existing algorithms, providing a more innovative technical path for cross-domain face liviality detection."

Journal

The effect of Tibolone treatment on depression, anxiety and mood in women: a meta-analysis and systematic review of randomized controlled trials. (PubMed, Arch Womens Ment Health) - "Tibolone significantly improved depressive symptoms in women, with non-significant trends in anxiety and mood. However, due to high heterogeneity, risk of bias in some studies, and limited number of trials for anxiety and mood outcomes, findings should be interpreted with caution."

Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

EFFECTS OF TIBOLONE ON MUSCLE STRENGTH AND BODY COMPOSITION IN EARLY POSTMENOPAUSAL KOREAN WOMEN: A PROSPECTIVE COHORT STUDY (FIGO 2025) - "Tibolone therapy may increase lean and skeletal muscle mass in early postmenopausal women, although changes in muscle strength were not evident. While within-group analysis showed significant gains in lean mass, between-group comparisons did not reach statistical significance. These findings suggest a potential benefit of tibolone on body composition that warrants further investigation in larger cohorts."

Clinical

Tibolone Improves Motor Recovery and Regulates Neuroinflammation and Gliosis in a Model of Traumatic Spinal Cord Injury. (PubMed, Int J Mol Sci) - "Our findings showed that Tib regulated pro- and anti-inflammatory cytokine levels at 3 h and 3, 7, and 14 days post-SCI. Furthermore, Tib administered orally for 15 days reduced gliosis markers and favored tissue preservation and motor function recovery after SCI."

Journal • CNS Disorders • Inflammation • Orthopedics • GFAP

Cardiovascular Risk Associated with Tibolone Use in Postmenopausal Women. (PubMed, J Menopausal Med) - No abstract available

Journal • Cardiovascular

Corneal enzymatic digestion resistance in the presence of oestradiol and oestradiol plus selective tissue oestrogenic activity regulators (STEAR). (PubMed, BMJ Open Ophthalmol) - "Oestradiol significantly reduces corneal enzymatic digestion resistance. When combined with the STEAR, tibolone, there is a further decrease in stromal enzymatic digestion resistance. These results suggest that high oestradiol levels could have a significant impact on corneal conditions characterised by elevated collagenase activity, such as corneal ectasias (eg, keratoconus) and infectious keratitis. Importantly, the employment of STEAR therapy, such as tibolone, may amplify the effects of oestradiol."

Journal • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • ER